{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:32:30Z","timestamp":1793298750386,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic dysfunction-associated fatty liver disease [MAFLD, formerly known as nonalcoholic fatty liver disease (NAFLD)] is one of the most important causes of liver disease worldwide, while cardiovascular disease (CVD) is still one of the main causes of morbidity and mortality worldwide, and the two are closely related. This study aimed to investigate the risk of CVD incidence or CVD-related mortality (CVD mortality) in patients diagnosed with MAFLD under new concepts and new diagnostic criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched English databases PubMed, Web of Science, Embase, and Cochrane Library for relevant literature. The language was restricted to English.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By 22 January 2022, 556 published studies were obtained through preliminary retrieval, and 10 cohort studies were included in this study. All statistical analyses were performed using Review Manager 5.2 software. Compared with the control group, patients in the MAFLD group had a significantly higher relative risk of CVD incidence or CVD mortality during the follow-up, with an RR rate of 1.95 (95% CI 1.76\u20132.17, <jats:italic>p<\/jats:italic> &amp;lt; 0.01). The incidence of CVD in the MAFLD group was more than twice that in the control group (RR 2.26, 95% CI 2.00\u20132.54, <jats:italic>p<\/jats:italic> &amp;lt; 0.01). The mortality rate of CVD was 1.57 times higher than that in the control group (RR 1.57, 95% CI 1.42\u20131.72, <jats:italic>p<\/jats:italic> &amp;lt; 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients diagnosed with MAFLD alone had higher cardiovascular mortality than those diagnosed with NAFLD alone based on the available data.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.934225","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T06:39:18Z","timestamp":1663310358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Wen","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiake","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongran","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-018-1040-1","article-title":"Current and emerging therapies for non-alcoholic fatty liver disease","volume":"79","author":"Patel","year":"2019","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13994","article-title":"Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis","volume":"39","author":"Morrison","year":"2019","journal-title":"Liver Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8825615","DOI":"10.1155\/2020\/8825615","article-title":"Acute coronary syndromes and nonalcoholic fatty liver disease: \u201cUn affaire de coeur\u201d","volume":"2020","author":"Ismaiel","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.08.011","article-title":"The role of nonalcoholic fatty liver disease on cardiovascular manifestations and outcomes","volume":"22","author":"Kovalic","year":"2018","journal-title":"Clin Liver Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.1038\/s41598-019-47687-3","article-title":"Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: A meta-analysis","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13519","article-title":"Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches","volume":"51","author":"Dongiovanni","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-05-21-5974","article-title":"Updates in fatty liver disease: Pathophysiology, diagnosis and management","volume":"50","author":"Gofton","year":"2021","journal-title":"Aust J Gen Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245762","article-title":"Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study","volume":"16","author":"Niriella","year":"2021","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2672516","DOI":"10.1155\/2021\/2672516","article-title":"Efficacy and safety of shexiang baoxin pill for coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis","volume":"2021","author":"Wei","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.021","article-title":"The global burden of cardiovascular diseases and risks: A compass for global action","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-2517-9_1","article-title":"Coronary artery disease: From mechanism to clinical practice","volume":"1177","author":"Shao","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B20","volume-title":"Cardiovascular disease. 2021","author":"Olvera Lopez","year":"2022"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the united states","volume":"75","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693507","article-title":"NAFLD or MAFLD: Which has closer association with all-cause and cause-specific mortality?-results from NHANES III","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.12.033","article-title":"The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants","author":"Liu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab339","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD)-rather a bystander than a driver of mortality","volume":"106","author":"Semmler","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10252-0","article-title":"Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13706","article-title":"MAFLD: Renovation of clinical practice and disease awareness of fatty liver","volume":"52","author":"Kawaguchi","year":"2021","journal-title":"Hepatol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10157-y","article-title":"Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD","volume":"15","author":"Guerreiro","year":"2021","journal-title":"Hepatol Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach","volume":"51","author":"Tsutsumi","year":"2021","journal-title":"Hepatol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: Pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13331","article-title":"Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-systematic review","volume":"50","author":"Ismaiel","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00202","article-title":"Cardiovascular risk in fatty liver disease: The liver-heart axis-literature review","volume":"6","author":"Ismaiel","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.3390\/jcm10215194","article-title":"Relationship between adipokines and cardiovascular ultrasound parameters in metabolic-dysfunction-associated fatty liver disease","volume":"10","author":"Ismaiel","year":"2021","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/ijms18061321","article-title":"Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction","volume":"18","author":"Achari","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M206083200","article-title":"Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis","volume":"277","author":"Matsuda","year":"2002","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000042707.50032.19","article-title":"Adiponectin reduces atherosclerosis in apolipoprotein e-deficient mice","volume":"106","author":"Okamoto","year":"2002","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1753944719880448","DOI":"10.1177\/1753944719880448","article-title":"Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris","volume":"13","author":"Duman","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41387-022-00182-7","article-title":"Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: A cross-sectional analysis","volume":"12","author":"Ismaiel","year":"2022","journal-title":"Nutr Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.09.004","article-title":"Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"50","author":"Wijarnpreecha","year":"2018","journal-title":"Dig Liver Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"213737","DOI":"10.1155\/2015\/213737","article-title":"Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: A systematic review and meta-analysis","volume":"2015","author":"Bonci","year":"2015","journal-title":"BioMed Res Int"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.934225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T06:39:20Z","timestamp":1663310360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.934225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":43,"alternative-id":["10.3389\/fendo.2022.934225"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.934225","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"934225"}}